All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The ongoing, open-label phase II PILOT trial (NCT03483103) is the first study to assess the efficacy and safety of lisocabtagene maraleucel (liso-cel), as a second-line treatment option in patients with relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL) following the first-line immunotherapy, who are not eligible for high-dose chemotherapy and hematopoietic stem cell transplant (HSCT) because of their age, performance status or comorbidities1. There is an unmet need for an established standard of care in the treatment of this patient population who have a poor prognosis. Liso-cel, is a CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ CAR T+ cells. The interim results of this phase II trial were published by Alison R. Sehgal, University of Pittsburgh Medical Center, US, and colleagues, and presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Meeting2.
Preliminary data of this trial were presented during the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.
The ongoing PILOT study is investigating the safety, antitumor activity, and pharmacokinetics of liso-cel in transplant noneligible (TNE) patients with R/R large B-cell lymphoma (LBCL). Key eligibility criteria include:
Primary endpoint: Objective response rate
Secondary endpoints: Adverse events, complete response rate, duration of response, pharmacokinetic profile, estimated progression-free survival, event-free survival, overall survival, laboratory abnormalities, and health-related quality of life
Baseline characteristics are presented in Table 1. The median age was 72 years (range 53–85), and the vast majority of patients were 65 years and older (86%). Being aged 70 years and above was the most common reason for ineligibility for transplantation (76%), followed by an ECOG PS of 2 (31%) and creatinine clearance < 60 mL/min (28%). A high proportion of patients (79%) had adverse prognostic features. 59% of patients were treated in an inpatient setting and 41% treated as outpatients.
Table 1. Patient characteristics2
ABC, activated B-cell; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; FL3B, follicular lymphoma Grade 3B; GCB, germinal center B-cell; HCT-CI, Hematopoietic Cell Transplantation-specific Comorbidity Index; LDH, lactate dehydrogenase; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified; SPD, sum of the product of perpendicular diameters; TNE, transplant noneligible |
|
Characteristic, n (%) |
Patients receiving liso-cel (n = 29) |
---|---|
Male sex |
18 (62) |
B-cell NHL subtypes DLBCL NOS Transformed FL High-grade B-cell lymphoma FL3B |
14 (48) 5 (17) 9 (31) 1 (3) |
LDH ≥ 500 U/L |
4 (14) |
SPD ≥ 50 cm2, n = 27 |
10 (37) |
HCT-CI score, median (range), n = 27 |
3 (0-9) |
Prognostic factors Double-/triple-hit lymphoma Refractory Relapsed within < 1 year ≥ 1 prognostic factor ≥ 1 TNE criteria and ≥ 1 prognostic factor |
9 (31) 15 (52) 6 (21) 23 (79) 23 (79) |
Cell of origin ABC, non-GCB GCB Unknown/unreported |
7 (24) 10 (34.5) 12 (41) |
The objective response rate was 89% (95% confidence interval [CI], 71–98) at a median follow-up of 5 months, and 15 responses were ongoing as of the cutoff date. An objective response was achieved in all patients with ≥ partial response within 30 days of treatment. The complete response rate was 56%, and the partial response rate was 33%. Three patients had disease progression and were treated with pembrolizumab (n = 2) and rituximab plus chemotherapy (n = 1). The probability of durable response at 3 months and 6 months was estimated to be 63% (95% CI, 37–81) and 53% (95% CI, 25–75), respectively.
The median time to peak CAR T-cell levels of liso-cel was Day 11 (Day 11, Day 15).
The most common treatment-emergent adverse events (TEAEs) were cytopenias. In total, 69% of patients experienced grade 3–4 TEAEs (Table 2). One patient experienced a Grade 5 TEAE of infection on Day 81, which was not considered to be related to the treatment with liso-cel.
Table 2. Grade 3–4 TEAEs in ≥ 15% of patients2
TEAEs, treatment-emergent adverse events *Neutropenia, thrombocytopenia, or anemia not resolved at Day 29 |
|
TEAEs, n (%) |
Grade 3–4 (N = 29) |
---|---|
Any TEAEs |
20 (69) |
Neutropenia |
10 (34.5) |
Leukopenia |
6 (21) |
Lymphopenia |
6 (21) |
Thrombocytopenia |
5 (17) |
Prolonged cytopenia* |
8 (28) |
Six patients experienced Grade 1–2 cytokine release syndrome (CRS) and no CRS events of Grade 3–5 occurred. Median time to onset of CRS was 5 days (range, 3–12) with a median resolution in 2.5 days (range, 1–4). Neurological events (NE) occurred in only three patients (Grade 1–2, n = 1; Grade 3, n = 2). Median time to onset of NE was 8 days (range, 7–8) with a median resolution in 4 days (range, 1–5). Three (10%) patients required tocilizumab and a corticosteroid for CRS, while two patients (7%) required a corticosteroid for NE. The number of death events was 3.
The interim results indicate that second-line treatment with liso-cel in this elderly, high-risk patient population who were ineligible for HSCT was associated with durable responses, including CRs with a high overall response rate. The benefit-risk profile was similar to previously reported in later-line settings.
Liso-cel therapy may be an appropriate second-line treatment option in patients with R/R aggressive large B-cell NHL following first-line immunotherapy who are not eligible for high-dose chemotherapy and transplantation; however, further evaluation and data are warranted.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?